EC approves argenx’s efgartigimod alfa for CIDP treatment
The approval is supported by the outcomes from the ADHERE trial.
Approvals
Novartis’ ribociclib approved in Canada for early breast cancer
Tisento’s MELAS treatment receives fast track status from FDA
Averoa secures EC authorisation for oral CKD treatment
FDA approves MSD’s Keytruda to treat head and neck cancer
FDA approves label expansion of AbbVie hepatitis C therapy
Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
